Treatment of Genotype 3 Cirrhotic Patients with 12 Weeks Sofosbuvir/Velpatasvir with or without Ribavirin: Real Life Experience from Italy

被引：0

作者：

Pasulo, Luisa ^{[1
]}

Gambato, Martina ^{[2
,3
]}

Spinetti, Angiola ^{[4
]}

D'Ambrosio, Roberta ^{[5
]}

Puoti, Massimo ^{[6
]}

Ciancio, Alessia ^{[7
]}

Di Marco, Vito ^{[8
]}

Calvaruso, Vincenza ^{[9
]}

Colombatto, Piero ^{[10
]}

Brunetto, Maurizia R. ^{[10
]}

Schiavini, Monica ^{[11
]}

Fabris, Paolo ^{[12
]}

Sacchi, Paolo ^{[13
]}

Gulminetti, Roberto ^{[13
]}

Carolo, Giada ^{[14
]}

Scotton, Piergiorgio ^{[15
]}

Pozzan, Caterina ^{[16
]}

Vinci, Maria ^{[6
]}

Vigano, Mauro ^{[17
]}

Lombardi, Andrea ^{[18
]}

Lobello, Salvatore ^{[19
]}

Zuin, Massimo ^{[20
]}

Aghemo, Alessio ^{[21
,22
]}

Rumi, Maria Grazia ^{[17
]}

Manfrin, Vinicio ^{[12
]}

Foppa, Caterina Valeria Uberti ^{[23
]}

Panese, Sandro

Paon, Veronica

Pan, Angelo ^{[24
]}

Spinelli, Ombretta ^{[25
]}

Monforte, Antonella D'Arminio ^{[20
]}

Colli, Agostino ^{[26
]}

Spinzi, Giancarlo ^{[27
]}

Russo, Francesco Paolo ^{[2
,3
]}

Chemello, Liliana ^{[28
]}

Vincenzi, Valter ^{[29
]}

Grossi, Paolo Antonio ^{[30
]}

Buscarini, Elisabetta ^{[31
]}

Soria, Alessandro ^{[32
]}

Menzaghi, Barbara ^{[33
]}

Mendeni, Monia ^{[4
]}

Soffredini, Roberta ^{[5
]}

Colpani, Maria ^{[34
]}

Zaltron, Serena ^{[4
]}

Gori, Andrea ^{[35
]}

Del Poggio, Paolo ^{[1
]}

Giorgini, Alessia ^{[20
]}

Cologni, Giuliana ^{[36
]}

Cartabellotta, Fabio ^{[37
]}

Di Lorenzo, Francesco ^{[38
]}

机构：

[1] Asst Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy

[2] Padova Univ Hosp, Multivisceral Transplant Unit, Padua, Italy

[3] Padova Univ Hosp, Gastroenterol, Padua, Italy

[4] Asst Brescia, Rete HCV Brescia, Brescia, Italy

[5] Univ Milan, Fdn Irccs Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, CRC aMea Migliavacca Ctr Liver Dis, Milan, Italy

[6] Asst Grande Osped Metropolitano Niguarda, Hepatitis Ctr, Milan, Italy

[7] Univ Turin, Gastroenterol, Turin, Italy

[8] Univ Palermo, Sez Gastroenterol & Epatol, Dipartimento Biomed Med Interna & Specialist Di B, Palermo, Italy

[9] P Giaccone Univ Hosp, Gastroenterol, Palermo, Italy

[10] Univ Hosp Pisa, Hepatol Unit, Pisa, Italy

[11] Sacco Milano, Fbf, Div Malattie Infett Asst 1, Milan, Italy

[12] Malattie Infett Vicenza, Vicenza, Italy

[13] Irccs Policlin San Matteo, Div Infect & Trop Dis, Pavia, Italy

[14] Azienda Osped Verona, Malattie Infett, Verona, Italy

[15] Azienda Osped Treviso, Malattie Infett, Treviso, Italy

[16] Azienda Osped Venezia, Gastroenterol, Venice, Italy

[17] San Giuseppe Hosp, Hepatol, Milan, Italy

[18] Univ Pavia, Malattie Infett Unita Malattie Infett Trop & Epat, Pavia, Italy

[19] OS Antonio Padova, Gastroenterol, Padua, Italy

[20] Rete HCV Asst Santi Paolo & Carlo, Milan, Italy

[21] Humanitas Res Hosp, Internal Med & Hepatol, Rozzano, MI, Italy

[22] Humanitas Univ, Rozzano, Italy

[23] Osped San Raffaele, Segrate, Italy

[24] Asst Cremona, Infect Dis, Cremona, Italy

[25] Asst Lariana, Med, Como, Italy

[26] Asst Lecco, Med, Lecce, Italy

[27] Valduce Hosp, Como, Italy

[28] Azienda Osped Univ Padova, Clin Med 5, Padua, Italy

[29] Azienda Osped Belluno, Med Gen, Belluno, Italy

[30] Univ Insubria Varese, Malattie Infett, Varese, Italy

[31] Asst Crema, Gastroenterol, Crema, Italy

[32] Asst Monza, San Gerardo Hosp, Infect Dis, Monza, Italy

[33] Busto Arsizio Hosp, Infect Dis, Busto Arsizio, Italy

[34] Asst Papa Giovanni XXIII, Bergamo, Italy

[35] San Gerardo Hosp, Monza, Italy

[36] Asst Papa Giovanni XXIII, Bergamo HCV Network 1, Bergamo, Italy

[37] Osped Buccheri La Feria, UOC Med Interna, Palermo, Italy

[38] Arnas Osped Civ, Infect Dis, Palermo, Italy

[39] Policlin Messina, Med & Epatol, Messina, Italy

[40] Osped Papardo, Infect Dis, Messina, Italy

[41] Osped Modica, Infect Dis, Modica, Italy

[42] Osped Comiso, Comiso, Italy

[43] Rete HCV Asst Santi Paolo & Carlo, Milan, Italy

[44] Asst Sacco, Infect Dis, Milan, Italy

[45] Quovadis Assoc, Bova Marina, Italy

[46] Univ Milan, Milan, Italy

[47] Univ Padua, Dipartimento Med Mol, Padua, Italy

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

592

引用

页码：351A / 352A

页数：2

共 50 条

[11] Sofosbuvir/Velpatasvir plus Ribavirin for chronic hepatitis C virus genotype 3 infected cirrhotic patients with or without HIVor HBV coinfection: real-world experience from southwest China
Wu, Ti
Wu, Ti
Huang, Kang
Li, Xiaofei
Lu, Nihong
Zhao, Zhirong
Wu, Lei
Bai, Jingsong
Li, Junyi
Li, Haiwen
Du, Yingrong
JOURNAL OF HEPATOLOGY, 2023, 78 : S1209 - S1210
[12] Cost-effectiveness analysis of the use of daclatasvir plus sofosbuvir plus ribavirin (16 weeks and 12 weeks) vs sofosbuvir plus ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
Restelli, Umberto
Alberti, Alfredo
Lazzarin, Adriano
Bonfanti, Marzia
Nappi, Carmela
Croce, Davide
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (01): : 37 - 44
[13] Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
Gane, Edward J.
Hyland, Robert H.
An, Di
Svarovskaia, Evguenia
Pang, Phillip S.
Brainard, Diana
Stedman, Catherine A.
GASTROENTEROLOGY, 2015, 149 (06) : 1454 - +
[14] Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes
Boyle, A.
Marra, F.
Reilly, E.
Fleming, C.
Heydtmann, M.
Fox, R.
Priest, M.
Morris, J.
Barclay, S.
JOURNAL OF HEPATOLOGY, 2018, 68 : S256 - S257
[15] Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study
Pianko, S.
Cooper, C.
Brown, A.
Forton, D.
Nahass, R.
George, J.
Barnes, E.
Brainard, D.
Massetto, B.
Lin, M.
Mchutchinson, J.
Subramanian, G. M.
Agarwal, K.
Foster, G.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 90 - 90
[16] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
G. Shiha
R. Soliman
M. ElBasiony
A. A. Hassan
N. N. H. Mikhail
Hepatology International, 2018, 12 : 339 - 347
[17] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
Shiha, G.
Soliman, R.
ElBasiony, M.
Hassan, A. A.
Mikhail, N. N. H.
HEPATOLOGY INTERNATIONAL, 2018, 12 (04) : 339 - 347
[18] Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis
Esteban, Rafael
Pineda, Juan A.
Luis Calleja, Jose
Casado, Marta
Rodriguez, Manuel
Turnes, Juan
Morano Amado, Luis Enrique
Maria Morillas, Rosa
Forns, Xavier
Pascasio Acevedo, Juan Manuel
Andrade, Raul J.
Rivero, Antonio
Antonio Carrion, Jose
Lens, Sabela
Riveiro-Barciela, Mar
McNabb, Brian
Zhang, Gulan
Camus, Gregory
Stamm, Luisa M.
Brainard, Diana M.
Subramanian, G. Mani
Buti, Maria
GASTROENTEROLOGY, 2018, 155 (04) : 1120 - +
[19] Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
Ferret, M. B.
Pineda, J.
Panero, J. L. C.
Rodriguez, M.
Morillas, R. M.
Pascasio, J. M.
Rivero, A.
Mcnabb, B.
Zhang, G.
Camus, G.
Stamm, L.
Brainard, D.
Subramanian, M.
Carrion, J. A.
Andrade, R. J.
Amado, L. E. M.
Turnes, J.
Lens, S.
Casado, M.
Esteban, R.
JOURNAL OF HEPATOLOGY, 2018, 68 : S20 - S21
[20] A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study
Foster, Graham R.
Thompson, Alex J.
Ruane, Peter J.
Borgia, Sergio M.
Dore, Gregory
Workowski, Kimberly
Hyland, Robert H.
Wang, Jing
Svarovskaia, Evguenia S.
Stamm, Luisa M.
Brainard, Diana M.
Subramanian, Mani
McHutchison, John G.
Berg, Thomas
Agarwal, Kosh
Conway, Brian
Feld, Jordan J.
Willems, Bernard E.
Roberts, Stuart K.
HEPATOLOGY, 2016, 64 : 135A - 136A

← 1 2 3 4 5 →